

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	25.2	91.1	(57.8-136.8)	Male	19	15.7	121.3	(73.0-189.4)
Female	6	9.1	66.3	(24.2-144.3)	Female	9	12.6	71.5	(32.6-135.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.0	159.6	(68.7-314.6)	Male	3	4.1	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	15	13.6	110.3	(61.7-181.9)
Female	90	94.9	94.9	(76.3-116.6)	Female	11	11.8	93.6	(46.7-167.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	4.1	121.4	(39.1-283.3)	Male	5	10.2	49.2	(15.9-114.8)
<u>Colon / Rectum</u>					Female	6	4.5	132.3	(48.3-288.1)
Male	27	37.8	71.4	(47.0-103.9)	<u>Ovary</u>				
Female	39	33.0	118.0	(83.9-161.3)	Female	3	10.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.8	117.7	(50.7-231.8)	Male	3	7.6	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	9	7.3	123.0	(56.1-233.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	113	108.0	104.7	(86.2-125.8)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	6.1	nc	(nc-nc)
Male	7	12.2	57.4	(23.0-118.3)	Female	1	3.3	nc	(nc-nc)
Female	7	7.2	97.4	(39.0-200.6)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.6	165.1	(60.3-359.4)
Male	4	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	13	11.3	115.1	(61.2-196.8)
Male	13	8.3	157.0	(83.5-268.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.1	130.8	(56.3-257.8)	Female	23	21.2	108.6	(68.8-163.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.8	103.6	(37.8-225.4)	Male	347	354.9	97.8	(87.8-108.6)
Female	1	1.8	nc	(nc-nc)	Female	323	317.9	101.6	(90.8-113.3)
<u>Lung and Bronchus</u>									
Male	53	49.8	106.4	(79.7-139.1)					
Female	50	45.3	110.3	(81.9-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;